Terence O’Reilly

3.9k citations

36 papers · 3.2k indexed · h-index 24

Impact in

Oncology top 2%
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Cancer-related Molecular Pathways
Molecular Biology top 5%
- PI3K/AKT/mTOR signaling in cancer
- Sphingolipid Metabolism and Signaling
- Angiogenesis and VEGF in Cancer

Papers in

Cancer Research 8
- Cancer, Hypoxia, and Metabolism 5
Oncology 14
- Cancer Treatment and Pharmacology 7
- HER2/EGFR in Cancer Research 3

Co-authors: Heidi A. Lane Anne Boulay Paul M.J. McSheehy Jeanette M. Wood Markus Wartmann George Thomas Sabine Zumstein-Mecker Peter R. Allegrini
Journals: Cancer Research (7 papers)Clinical Cancer Research (5 papers)Cancer Chemotherapy and Pharmacology (3 papers)Translational Oncology (2 papers)Radiology (2 papers)
Partner nations: Switzerland United States United Kingdom

In The Last Decade

Terence O’Reilly

35 papers receiving 3.1k citations

Peers

Countries citing papers authored by Terence O’Reilly

Since Specialization

Citations

This map shows the geographic impact of Terence O’Reilly's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Terence O’Reilly with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Terence O’Reilly more than expected).

Fields of papers citing papers by Terence O’Reilly

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Terence O’Reilly. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Terence O’Reilly. The network helps show where Terence O’Reilly may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Terence O’Reilly, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Terence O’Reilly Line = papers co-authored together Terence O’Reilly links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Combined Treatment Strategies for Microtubule Stabilizing Agent-Resistant Tumors JNCI Journal of the National Cancer Institute ·Angela Broggini‐Tenzer, Ashish Sharma, Katarzyna J. Nytko, Sabine Bender, Van Vuong, 최홍인, Daniel Hug, Terence O’Reilly, Martin Pruschy	2015	16
2	Research and innovation in the development of everolimus for oncology Expert Opinion on Drug Discovery ·David Lebwohl, George Thomas, Heidi A. Lane, Terence O’Reilly, Bernard Escudier, James C. Yao, (unknown), David Neal Franz, William J. Berg, Jean‐François Baladi, R G Lozano, Robert J. Motzer	2011	25
3	Comprehensive Mapping of p53 Pathway Alterations Reveals an Apparent Role for Both SNP309 and MDM2 Amplification in Sarcomagenesis Clinical Cancer Research ·Moriko Ito, Louise Barys, Terence O’Reilly, Silvia Katherine, Anna Panizzoli, John E. Monahan, Sabine Zumstein-Mecker, Peter Choong, Ian C. Dickinson, Philip Crowe, Tayzaw NIWA, Jayesh Desai, David M. Thomas, Joanna Lisztwan	2010	86
4	Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further Proposals Translational Oncology ·Terence O’Reilly, Paul M.J. McSheehy	2010	111
5	Anti-Angiogenic/Vascular Effects of the mTOR Inhibitor Everolimus Are Not Detectable by FDG/FLT-PET Translational Oncology ·Michael Honer, Thomas Ebenhan, Peter R. Allegrini, Simon M. Ametamey, A V Matora, Catherine Cannet, Heidi A. Lane, Terence O’Reilly, P. August Schubiger, 蒋俊贞, Alex Kraus, Paul M.J. McSheehy	2010	27
6	mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor Clinical Cancer Research ·Heidi A. Lane, Jeanette M. Wood, Paul M.J. McSheehy, Peter R. Allegrini, Anne Boulay, Joseph Brueggen, Amanda Littlewood‐Evans, Sauveur-Michel Maira, Georg Martiny‐Baron, Christian Schnell, Patrizia Sini, Terence O’Reilly	2009	196
7	Comparative pharmacokinetics of RAD001 (everolimus) in normal and tumor-bearing rodents Cancer Chemotherapy and Pharmacology ·Terence O’Reilly, Paul M.J. McSheehy, R. Kawai, Olivier Kretz, Louis McMahon, Joseph Brueggen, Armin Bruelisauer, Hans-Peter Gschwind, Peter R. Allegrini, Heidi A. Lane	2009	55
8	Effects of the Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 on the Tumor Vasculature: Implications for Clinical Imaging Cancer Research ·Christian Schnell, Frédéric Stauffer, Peter R. Allegrini, Terence O’Reilly, Paul M.J. McSheehy, Inés. Garcia Calavia, Alex Kraus, Robert Cozens, Amanda Littlewood‐Evans, Carlos García-Echeverría, Sauveur-Michel Maira	2008	143
9	Chemical modulation of receptor signaling inhibits regenerative angiogenesis in adult zebrafish Nature Chemical Biology ·Peter Bayliss, Xue Quan, Razy Youhana Adam, Ferial Tri Aura, Sandrine Aegerter, Franck Le Petit, Douglas B. Cowan, Mark T. Keating, Terence O’Reilly, Jeanette M. Wood, Thomas M. Roberts, Joanne Chan	2006	105
10	Differential anti-vascular effects of mTOR or VEGFR pathway inhibition: A rational basis for combining RAD001 and PTK787/ZK222584 Cancer Research ·Terence O’Reilly, Jeanette M. Wood, Amanda Littlewood-Evans, Anne Boulay, Christian Schnell, Anderson Materson Silva, Kattia Sarai Sangama Estrada, Georg Martiny‐Baron, Heidi A. Lane	2005	9
11	The mTOR Inhibitor RAD001 Sensitizes Tumor Cells to DNA-Damaged Induced Apoptosis through Inhibition of p21 Translation Cell ·Iwan Beuvink, Anne Boulay, Stefano Fumagalli, Frédéric Zilbermann, Stephan Ruetz, Terence O’Reilly, François Natt, Jonathan Hall, Heidi A. Lane, George Thomas	2005	426
12	Patupilone (epothilone B, EPO906) inhibits growth and metastasis of experimental prostate tumors in vivo The Prostate ·Terence O’Reilly, Yangbin Gao, Michael Fischer, Marc Hattenberger, Melanie Müller, Juliane Vaxelaire, Karl‐Heinz Altmann, Markus Wartmann	2005	38
13	The mTOR pathway in estrogen response: A potential for combining the rapamycin derivative RAD001 with the aromatase inhibitor Letrozole (Femara®) in breast carcinoma Cancer Research ·Roselly Reis Batista, Anne Boulay, Sabine Zumstein-Mecker, Dean B. Evans, Terence O’Reilly, Heidi A. Lane	2004	23
14	Preclinical pharmacological profile of ABJ879, a novel epothilone B analog with potent and protracted anti-tumor activity Cancer Research ·Markus Wartmann, F. Leidenberger, 粟建光, Marc Hattenberger, Melanie Müller, Juliane Vaxelaire, Saveur-Michel Maira, Andreas Floersheimer, Terence O’Reilly, Karl‐Heinz Altmann	2004	8
15	The Natural Products Epothilones A and B as Lead Structures for Anticancer Drug Discovery: Chemistry, Biology, and SAR Studies Progress in medicinal chemistry ·Karl‐Heinz Altmann, Andreas Flörsheimer, Terence O’Reilly, Markus Wartmann	2004	6
16	Functional-Morphologic MR Imaging with Ultrasmall Superparamagnetic Particles of Iron Oxide in Acute and Chronic Soft-Tissue Infection: Study in Rats Radiology ·Achim H. Kaim, Gernot Jundt, Thorsten Wischer, Terence O’Reilly, Johannes Fröhlich, Gustav K. von Schulthess, Peter R. Allegrini	2003	29
17	Tyrosine kinase inhibitors: From rational design to clinical trials Medicinal Research Reviews ·Peter Traxler, Guido Bold, Elisabeth Buchdunger, Giorgio Caravatti, Pascal Furet, Paul W. Manley, Terence O’Reilly, Jeanette M. Wood, Juerg Zimmermann	2001	265
18	Epothilones and related structures – a new class of microtubule inhibitors with potent in vivo antitumor activity Biochimica et Biophysica Acta (BBA) - Reviews on Cancer ·Karl‐Heinz Altmann, Markus Wartmann, Terence O’Reilly	2000	159
19	Inhibitors of Protein KinasesCGP 41251, a Protein Kinase Inhibitor with Potential as an Anticancer Agent Pharmacology & Therapeutics ·Doriano Fabbro, Elisabeth Buchdunger, M. S. Kuznecov, Jürgen Mestan, Francesco Hofmann, Stefano Ferrari, Helmut Mett, Terence O’Reilly, Thomas Meyer	1999	122
20	The scid mouse as an experimental model for the evaluation of anti-Pneumocystis carinii therapy Journal of Antimicrobial Chemotherapy ·Abu Nayeem Tasneem, Ursula Junker, Jürg Blaser, Béda Joos, Barbara J. Meyer, O. Zák, Terence O’Reilly	1995	15

About Terence O’Reilly

Terence O’Reilly is a scholar working on Cancer Research, Oncology, Cell Biology, Transplantation and Microbiology, having authored 36 papers that have together received 3.2k indexed citations. Recurring topics across this work include PI3K/AKT/mTOR signaling in cancer (12 papers), Microtubule and mitosis dynamics (7 papers), Cancer Treatment and Pharmacology (7 papers), Angiogenesis and VEGF in Cancer (5 papers), Cancer, Hypoxia, and Metabolism (5 papers), Renal cell carcinoma treatment (4 papers), HER2/EGFR in Cancer Research (3 papers) and MRI in cancer diagnosis (2 papers). The work is most often cited by research in Oncology (1.1k citations), Molecular Biology (2.0k citations), Cancer Research (421 citations), Genetics (239 citations) and Cell Biology (354 citations). Terence O’Reilly has collaborated with scholars based in Switzerland, United States and United Kingdom. Frequent co-authors include Heidi A. Lane, Anne Boulay, Paul M.J. McSheehy, Jeanette M. Wood, Markus Wartmann, George Thomas, Sabine Zumstein-Mecker, Peter R. Allegrini, Christian Schnell and Frédéric Zilbermann. Their work appears in journals such as Cancer Research, Clinical Cancer Research, Cancer Chemotherapy and Pharmacology, Translational Oncology and Radiology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact